journal
MENU ▼
Read by QxMD icon Read
search

Journal of Prevention of Alzheimer's Disease

journal
https://www.readbyqxmd.com/read/29616710/letter-to-editor-nanorobots-the-future-of-neurology-a-perspective-on-alzheimer-s-disease
#1
C Hooper, S Layé
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616709/development-of-azeliragon-an-oral-small-molecule-antagonist-of-the-receptor-for-advanced-glycation-endproducts-for-the-potential-slowing-of-loss-of-cognition-in-mild-alzheimer-s-disease
#2
A H Burstein, M Sabbagh, R Andrews, C Valcarce, I Dunn, L Altstiel
Increasing evidence supports the role of the Receptor for Advanced Glycation Endproducts (RAGE) in the pathology of Alzheimer's disease. Azeliragon (TTP488) is an orally bioavailable small molecule inhibitor of RAGE in Phase 3 development as a potential treatment to slow disease progression in patients mild AD. Preclinical studies in animal models of AD (tgAPPSwedish/London) have shown azeliragon to decrease Aβ plaque deposition; reduce total Aβ brain concentration while increasing plasma Aβ levels; decreases sAPPβ while increasing sAPPα; reduce levels of inflammatory cytokines; and slow cognitive decline and improve cerebral blood flow...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616708/strong-relationship-between-malnutrition-and-cognitive-frailty-in-the-singapore-longitudinal-ageing-studies-slas-1-and-slas-2
#3
L Chye, K Wei, M S Z Nyunt, Q Gao, S L Wee, T P Ng
BACKGROUND: Physical frailty is well known to be strongly associated with malnutrition, but the combined impact of physical frailty and cognitive impairment among non-demented older persons (cognitive frailty) on malnutrition prevalence is not well documented. DESIGN: Cross-sectional cohort study. SETTING AND PARTICIPANTS: Community-dwelling older Singaporeans aged ≥55y (n=5414) without dementia in the Singapore Longitudinal Ageing Study (SLAS-1 and SLAS-2)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616707/adherence-to-the-mediterranean-diet-is-not-related-to-beta-amyloid-deposition-data-from-the-women-s-healthy-ageing-project
#4
E Hill, C Szoeke, L Dennerstein, S Campbell, P Clifton
BACKGROUND: Research has indicated the neuroprotective potential of the Mediterranean diet. Adherence to the Mediterranean diet has shown preventative potential for Alzheimer's disease incidence and prevalence, yet few studies have investigated the impact of Mediterranean diet adherence on the hallmark protein; beta-amyloid. OBJECTIVES: To investigate the association between Mediterranean diet adherence and beta-amyloid deposition in a cohort of healthy older Australian women...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616706/the-integrated-alzheimer-s-disease-rating-scale-iadrs-findings-from-the-expedition3-trial
#5
A M Wessels, S W Andersen, S A Dowsett, E R Siemers
The Integrated Alzheimer's Disease (AD) Rating Scale (iADRS) is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). It demonstrates acceptable psychometric properties, and is effective in capturing both disease progression and separation of placebo and active drug effect. We assessed the performance of iADRS in the solanezumab EXPEDITION3 study, an 80-week, placebo-controlled study of individuals with mild AD dementia...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616705/a-literature-review-of-methodologies-used-in-randomized-clinical-trials-of-agitation-in-alzheimer-s-disease
#6
S Dubé, J T Megerian, R Malamut
Agitation is a common and burdensome symptom associated with Alzheimer's disease (AD). This is a narrative literature review of the designs and methods used in randomized clinical trials of agitation in patients with AD; sources range from published, to completed but not published, to ongoing studies in the past 10 years. Selection for review included blinded, randomized trials conducted to assess the effect of a pharmacological intervention for which agitation in patients with AD was among the prespecified end points...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616704/minimizing-the-sample-sizes-of-clinical-trials-on-preclinical-and-early-symptomatic-stage-of-alzheimer-disease
#7
J Luo, H Weng, J C Morris, C Xiong
BACKGROUND: Clinical trials of investigational drugs for Alzheimer disease (AD) increasingly focus on the prodromal (symptomatic) stage of the illness and now its preclinical (asymptomatic) stage. Sensitive and specific cognitive and functional endpoints are needed to track subtle cognitive and functional changes in the early and preclinical stages to minimize sample sizes in these trials. OBJECTIVES: To identify informative items in a standard clinical assessment protocol and a psychometric battery that are predictive of onset of dementia symptom...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616703/biomarker-and-clinical-trial-design-support-for-disease-modifying-therapies-report-of-a-survey-of-the-eu-us-alzheimer-s-disease-task-force
#8
J Cummings, N Fox, B Vellas, P Aisen, G Shan
BACKGROUND: Disease-modifying therapies are urgently needed for the treatment of Alzheimer's disease (AD). The European Union/United States (EU/US) Task Force represents a broad range of stakeholders including biopharma industry personnel, academicians, and regulatory authorities. OBJECTIVES: The EU/US Task Force represents a community of knowledgeable individuals who can inform views of evidence supporting disease modification and the development of disease-modifying therapies (DMTs)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616702/identifying-better-outcome-measures-to-improve-treatment-of-agitation-in-dementia-a-report-from-the-eu-us-ctad-task-force
#9
M Sano, M Soto, M Carrillo, J Cummings, S Hendrix, J Mintzer, A Porsteinsson, P Rosenberg, L Schneider, J Touchon, P Aisen, B Vellas, C Lyketsos
For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616701/diabetes-mellitus-and-cognitive-decline-prevention-should-not-be-delayed
#10
A J Sinclair
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616700/editorial-prevention-of-alzheimer-s-disease-in-chinese-populations-status-challenges-and-directions
#11
L Feng, J Li, J-T Yu, C Zhang, B Yang, B Vellas, C Li
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405240/letter-to-the-editor-responses-long-term-tea-consumption-and-depressive-and-anxiety-symptoms-in-elderly
#12
L Feng
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405239/letter-to-the-editor-long-term-tea-consumption-and-depressive-and-anxiety-symptoms-in-elderly
#13
B Joob, V Wiwanitkit
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405238/letter-to-the-editor-dementia-creating-a-knowledge-based-healthcare-profession
#14
C Scerri
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405237/the-relationship-of-omega-3-polyunsaturated-fatty-acids-in-red-blood-cell-membranes-with-cognitive-function-and-brain-structure-a-review-focussed-on-alzheimer-s-disease
#15
C Hooper, P De Souto Barreto, M Pahor, M Weiner, B Vellas
Significant research attention has focussed on the identification of nutraceutical agents for the prevention of cognitive decline as a natural means of cognitive preservation in the elderly. There is some evidence for a reduction of brain omega 3 polyunsaturated fatty acids (n-3 PUFAs) in normal aging and in Alzheimer's disease. n-3 PUFAs exhibit anti-inflammatory and anti-amyloidogenic properties as well as being able to reduce tau phosphorylation. Many observational studies have demonstrated a link between n-3 PUFAs and cognitive aging, and some, but not all, randomized controlled trials have demonstrated a benefit of n-3 PUFA supplementation on cognition, particularly in those subjects with mild cognitive impairment...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405236/combining-geospatial-analysis-with-dementia-risk-utilising-general-practice-data-a-systematic-review
#16
N Bagheri, K Wangdi, N Cherbuin, K J Anstey
Geographical information systems (GIS) and geospatial analysis techniques will help to identify significant dementia risk clusters (hotspots) across communities and will enable policy makers to target prevention interventions to the right place. This review synthesises the published literature on geospatial analysis techniques for quantifying and mapping dementia risk, and reviews available dementia risk assessment tools. A systematic literature review was undertaken in four medical and life sciences databases (PubMed, Cochrane Central, Embase, and Web of Sciences) from their inception to March 2017 for all articles relating to dementia...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405235/neuroprotective-effects-of-guarana-paullinia-cupana-mart-against-vincristine-in-vitro-exposure
#17
C F Veloso, A K Machado, F C Cadoná, V F Azzolin, I B M Cruz, A F Silveira
BACKGROUND: Vincristine (VCR) is not a specific chemotherapeutic drug, responsible for cause several side effects. In this sense, many natural products have been studied to reduce this problem. Objetives: To examine the guarana neuroprotective effect in mice brain and cerebellum cells against vincristine (VCR) exposition. DESIGN: An in vitro study was performed using mice brain and cerebellum mice in monolayer culture. First, cells were exposed to VCR (0.009 µM for 24 hours and 0...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405234/costs-and-resource-use-associated-with-alzheimer-s-disease-in-italy-results-from-an-observational-study
#18
G Bruno, M Mancini, G Bruti, G Dell'Agnello, C Reed
BACKGROUND: The GERAS II study aimed to assess societal costs and resource use associated with Alzheimer's disease (AD) for patients and their primary caregivers in Italy and Spain, stratified for different severity stages of AD at baseline. This report presents baseline results for Italy. DESIGN: GERAS II was a prospective, multicentre, observational study of routine care in AD. SETTING: Community-dwelling patients attending specialist secondary care centres (memory clinics/Alzheimer's Evaluation Units) and their primary informal caregivers were recruited into the study...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405233/the-value-of-pre-screening-in-the-alzheimer-s-prevention-initiative-api-autosomal-dominant-alzheimer-s-disease-trial
#19
S Rios-Romenets, M Giraldo-Chica, H López, F Piedrahita, C Ramos, N Acosta-Baena, C Muñoz, P Ospina, C Tobón, W Cho, M Ward, J B Langbaum, P N Tariot, E M Reiman, F Lopera
The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29405232/cognitive-frailty-and-incidence-of-dementia-in-older-persons
#20
H Shimada, H Makizako, K Tsutsumimoto, T Doi, S Lee, T Suzuki
BACKGROUND: Cognitive frailty may be a preventive or therapeutic target for preventing dementia and functional decline with age. OBJECTIVES: To examine the relationship between physical and cognitive frailty and the incidence of dementia in community-living older persons. DESIGN: A prospective cohort study. SETTING: General community in Japan. PARTICIPANTS: A total of 4072 persons aged ≥ 65 years...
2018: Journal of Prevention of Alzheimer's Disease
journal
journal
48972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"